Jump to content

StatPearls 2020: Buspirone


[La...]

Recommended Posts

StatPearls 2020: Buspirone

 

https://pubmed.ncbi.nlm.nih.gov/30285372/

 

 

Excerpt

 

Buspirone is an anxiolytic first synthesized in 1968 and patented in 1975. Initially, the drug was being developed as an antipsychotic but found not to be effective for psychosis, but it had anxiolytic features that were useful. Buspirone has recently come back into favor. This return to favor is mostly due to its decreased side-effect profile compared to other anxiolytic treatments. Buspirone's use is primarily for the treatment of generalized anxiety disorder (GAD). Typically, it is used as a second-line agent behind selective serotonin reuptake inhibitors (SSRIs) when a patient does not respond to or cannot tolerate the side effects of SSRIs. Buspirone has also been used as an augmentation agent to reduce SSRIs sexual side effects in particular. Unlike benzodiazepines and barbiturates, there is no associated risk of physical dependence or withdrawal with buspirone use due to the lack of effects on GABA receptors. However, buspirone has little efficacy as an acute anxiolytic as clinical effect typically takes 2 to 4 weeks to achieve.[1] Buspirone is FDA approved for the short and long-term treatment of GAD, as well as short-term symptomatic relief of anxiety. It is as effective as benzodiazepine treatment for GAD.

 

Full Paper:

 

https://www.ncbi.nlm.nih.gov/books/NBK531477/#article-18731.s1

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...